Jorge Sierra

Prognostic Impact of FLT3 ‐ ITD Microclones in AML : An EHA AML ‐Specialized Working Group Study

ABSTRACT The 2022 ELN recommendations reclassified fms‐like tyrosine kinase‐3 ( FLT3 )‐ITD mutated acute myeloid leukemia (AML) as intermediate‐risk, irrespective of allelic ratio (AR), and designated capillary electrophoresis (CE) as the preferred detection method. However, CE r...